TM

VISSAN BioLabs
for Sustainable Health
We are a small private laboratory of biopharmaceutical research located in Slovakia.
Deciphering the bioactive profile of secondary metabolites from natural products and exploring the therapeutic usefulness of various TLR agonists and combined approaches are at the core of our permanent research interests associated with in-house pharmaceutical development.
Our approach to developing modern neuro-immunotherapies across a broad spectrum of non-progressive and progressive neurological and neuropsychiatric disorders centers on the unifying role of sterile inflammation marked by a failure of resolution as a key contributor to disease progression.
Within a milieu of neuroendocrine-immune dysregulation sustained by DAMPs, subclinical exposure to non-cytotoxic PAMPs is emerging as a safe and promising therapeutic paradigm. By integrating PAMP-dependent signaling crosstalk, this strategy reconciles contextual pro-inflammatory and regulatory cues across immune-parenchymal interactions.
Our non-pathogenic, microbial-derived multiple TLR agonist, codenamed Sym9922, potentiates negative feedback signaling during maladaptive inflammatory states, shifting the resulting immune response toward regulatory control.
Broadly, resolving a neuroinflammatory insult or mood disturbance while restoring tissue homeostasis through in situ immune reprogramming is regarded as a physiologically sound strategy for functional recovery.
Compound
Mechanism of action/Modality
Indication
Development stage
Sym9922
Ischemic preconditioning through low-dose induction of TLR hyporeactivity to build tolerance against hypoxia-ischemia
Secondary stroke prevention (post-TIA).
Neuroprotection and modulation of neuroinflammation
Preclinical
Sym9922
Increased hippocampal neurogenesis, antidepressant-like effects (reversal of stress-induced anhedonia), improved cognitive function
Post-stroke and traumatic brain injury recovery.
Slowing or halting neurodegeneration, and enhancing adult neurogenesis in neurodegeneration-related cognitive decline.
Treatment of anhedonia and depressive disorders
Preclinical
VM71224
Modulation of the tumor immune microenvironment.
Induction of Th1 cytotoxic responses
Cancer immunotherapy
Discovery